Anaptysbio Stock Analysis
ANAB Stock | USD 21.50 0.90 4.02% |
AnaptysBio is undervalued with Real Value of 25.3 and Target Price of 29.75. The main objective of AnaptysBio stock analysis is to determine its intrinsic value, which is an estimate of what AnaptysBio is worth, separate from its market price. There are two main types of AnaptysBio's stock analysis: fundamental analysis and technical analysis.
The AnaptysBio stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and AnaptysBio's ongoing operational relationships across important fundamental and technical indicators.
AnaptysBio |
AnaptysBio Stock Analysis Notes
About 98.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 6.05. AnaptysBio had not issued any dividends in recent years. AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. Anaptysbio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people. For more info on AnaptysBio please contact the company at 858 362 6295 or go to https://www.anaptysbio.com.AnaptysBio Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. AnaptysBio's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding AnaptysBio or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
AnaptysBio generated a negative expected return over the last 90 days | |
AnaptysBio has high historical volatility and very poor performance | |
The company reported the previous year's revenue of 17.16 M. Net Loss for the year was (163.62 M) with loss before overhead, payroll, taxes, and interest of (78.51 M). | |
AnaptysBio currently holds about 442.15 M in cash with (120.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.66. | |
Over 98.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from zacks.com: AnaptysBio Upgraded to Buy What Does It Mean for the Stock |
AnaptysBio Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AnaptysBio previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
6th of March 2024 Upcoming Quarterly Report | View | |
9th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
6th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
AnaptysBio Largest EPS Surprises
Earnings surprises can significantly impact AnaptysBio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2021-08-09 | 2021-06-30 | -0.11 | -0.02 | 0.09 | 81 | ||
2019-08-08 | 2019-06-30 | -0.99 | -0.89 | 0.1 | 10 | ||
2018-03-05 | 2017-12-31 | -0.42 | -0.3 | 0.12 | 28 |
AnaptysBio Environmental, Social, and Governance (ESG) Scores
AnaptysBio's ESG score is a quantitative measure that evaluates AnaptysBio's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of AnaptysBio's operations that may have significant financial implications and affect AnaptysBio's stock price as well as guide investors towards more socially responsible investments.
AnaptysBio Stock Institutional Investors
Shares | Camber Capital Management Llc | 2024-06-30 | 500 K | Assenagon Asset Management Sa | 2024-09-30 | 475.4 K | Franklin Resources Inc | 2024-06-30 | 465.4 K | Geode Capital Management, Llc | 2024-06-30 | 452.1 K | Millennium Management Llc | 2024-06-30 | 373.8 K | 5am Venture Management, Llc | 2024-06-30 | 357.7 K | Dimensional Fund Advisors, Inc. | 2024-06-30 | 335.9 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 300.2 K | Parkman Healthcare Partners Llc | 2024-06-30 | 256.3 K | Ecor1 Capital, Llc | 2024-06-30 | 7.5 M | Fmr Inc | 2024-06-30 | 2.9 M |
AnaptysBio Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 648.44 M.AnaptysBio Profitablity
The company has Profit Margin (PM) of (2.9) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.76) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.76.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.36) | (0.38) | |
Return On Capital Employed | (0.40) | (0.42) | |
Return On Assets | (0.36) | (0.38) | |
Return On Equity | (1.86) | (1.95) |
Management Efficiency
AnaptysBio has return on total asset (ROA) of (0.1785) % which means that it has lost $0.1785 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6182) %, meaning that it created substantial loss on money invested by shareholders. AnaptysBio's management efficiency ratios could be used to measure how well AnaptysBio manages its routine affairs as well as how well it operates its assets and liabilities. As of November 13, 2024, Return On Tangible Assets is expected to decline to -0.38. In addition to that, Return On Capital Employed is expected to decline to -0.42. At present, AnaptysBio's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 9.5 M, whereas Total Assets are forecasted to decline to about 354.3 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 3.27 | 3.11 | |
Tangible Book Value Per Share | 3.27 | 3.11 | |
Enterprise Value Over EBITDA | (3.90) | (4.10) | |
Price Book Value Ratio | 6.55 | 6.22 | |
Enterprise Value Multiple | (3.90) | (4.10) | |
Price Fair Value | 6.55 | 6.22 |
Evaluating the management effectiveness of AnaptysBio allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The AnaptysBio Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Operating Margin (0.76) | Profit Margin (2.90) | Beta (0.24) | Return On Assets (0.18) | Return On Equity (1.62) |
Technical Drivers
As of the 13th of November 2024, AnaptysBio shows the risk adjusted performance of (0.07), and Mean Deviation of 3.31. AnaptysBio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.AnaptysBio Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. AnaptysBio middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for AnaptysBio. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
AnaptysBio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AnaptysBio insiders, such as employees or executives, is commonly permitted as long as it does not rely on AnaptysBio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AnaptysBio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
AnaptysBio Outstanding Bonds
AnaptysBio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AnaptysBio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most AnaptysBio bonds can be classified according to their maturity, which is the date when AnaptysBio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View |
AnaptysBio Predictive Daily Indicators
AnaptysBio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of AnaptysBio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 34704.9 | |||
Daily Balance Of Power | (0.55) | |||
Rate Of Daily Change | 0.96 | |||
Day Median Price | 21.99 | |||
Day Typical Price | 21.82 | |||
Price Action Indicator | (0.93) | |||
Period Momentum Indicator | (0.90) | |||
Relative Strength Index | 33.74 |
AnaptysBio Corporate Filings
8K | 5th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 24th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 17th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 16th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
14th of August 2024 Other Reports | ViewVerify | |
8K | 5th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 24th of July 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 19th of July 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
AnaptysBio Forecast Models
AnaptysBio's time-series forecasting models are one of many AnaptysBio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary AnaptysBio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About AnaptysBio Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how AnaptysBio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling AnaptysBio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as AnaptysBio. By using and applying AnaptysBio Stock analysis, traders can create a robust methodology for identifying AnaptysBio entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (9.54) | (10.01) | |
Operating Profit Margin | (9.58) | (10.06) | |
Net Loss | (9.54) | (10.01) | |
Gross Profit Margin | 0.86 | 0.90 |
Current AnaptysBio Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. AnaptysBio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. AnaptysBio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
29.75 | Strong Buy | 12 | Odds |
Most AnaptysBio analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand AnaptysBio stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of AnaptysBio, talking to its executives and customers, or listening to AnaptysBio conference calls.
AnaptysBio Stock Analysis Indicators
AnaptysBio stock analysis indicators help investors evaluate how AnaptysBio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading AnaptysBio shares will generate the highest return on investment. By understating and applying AnaptysBio stock analysis, traders can identify AnaptysBio position entry and exit signals to maximize returns.
Begin Period Cash Flow | 71.3 M | |
Common Stock Shares Outstanding | 26.9 M | |
Total Stockholder Equity | 88.1 M | |
Tax Provision | -4000.00 | |
Property Plant And Equipment Net | 18.3 M | |
Cash And Short Term Investments | 390.9 M | |
Cash | 36 M | |
Accounts Payable | 4.7 M | |
Net Debt | -18.2 M | |
50 Day M A | 32.6644 | |
Total Current Liabilities | 37.4 M | |
Other Operating Expenses | 174.2 M | |
Non Current Assets Total | 45.6 M | |
Non Currrent Assets Other | 256 K | |
Stock Based Compensation | 33.2 M |
Complementary Tools for AnaptysBio Stock analysis
When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |